FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Baxfendy recommended for approval in the EU
16 November
2026
Baxfendy
(baxdrostat) recommended for approval
in the EU for the treatment of adults with
hypertension
Based on Phase III results showing statistically significant and
clinically meaningful reductions in systolic blood pressure in
patients with uncontrolled or resistant hypertension
Baxfendy 2mg lowered office systolic blood pressure by 15.7 mmHg
from baseline in BaxHTN trial and 24-hour ambulatory systolic blood
pressure by 16.6 mmHg from baseline in Bax24 trial
If approved, Baxfendy will be the first and only aldosterone
synthase inhibitor in the EU
AstraZeneca's Baxfendy (baxdrostat) has been recommended for approval in
the European Union (EU) for the treatment of adults with arterial
hypertension insufficiently controlled with at least two
antihypertensive medicinal products. If approved,
Baxfendy
will be the first and only aldosterone
synthase inhibitor (ASI) in the EU, directly targeting aldosterone
to address a key biological driver of elevated blood
pressure.
The Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) based its positive opinion on
results from two pivotal Phase III trials in which
Baxfendy
demonstrated statistically significant
and clinically meaningful reductions in seated systolic blood
pressure (SBP) in patients with uncontrolled or resistant
hypertension, and 24-hour average ambulatory SBP in patients with
resistant hypertension.1,2
There are 1.4 billion people worldwide living with
hypertension.3
Approximately 50% of people already
taking two or more antihypertensive medications struggle with
persistently uncontrolled hypertension.4,5
About 70 million adults across Europe
have hypertension that remains uncontrolled despite treatment,
putting them at increased risk for cardiovascular disease and
premature death.3,6,7
Hypertension is the most prevalent and
significant modifiable cardiovascular risk factor worldwide,
accounting for more deaths and disability than any other modifiable
risk.8-10
Elevated aldosterone levels play a
central role in persistently uncontrolled hypertension and are
associated with a decline in kidney function and increased
cardiovascular risk.11-13
Dr. Bryan Williams, Chair of Medicine at University College London
and primary investigator for BaxHTN and Bax24, said: "The strength
of the research behind Baxfendy is a triumph of science and demonstrates its
potential as an important new class of treatment for people in
Europe living with persistently uncontrolled hypertension.
Epidemiological data indicate that a 10 mmHg decrease in systolic
blood pressure is associated with a roughly 20% lower risk of
serious cardiovascular events like heart attack and stroke,
underscoring why effective blood pressure lowering matters for
people living with uncontrolled hypertension."
Ruud Dobber, Executive Vice President and President,
BioPharmaceuticals Business Unit, AstraZeneca, said: "Hypertension
is often called the 'silent killer' and is a leading risk factor
for heart attack, stroke and dementia. This positive CHMP opinion
for Baxfendy marks a significant step toward bringing this
potential first-in-class innovation to patients in Europe. This
novel medicine reflects the strength of our pipeline across
interconnected cardiovascular, renal and metabolic diseases as we
deliver on our 2030 ambition to bring 20 new medicines to the
world."
In the BaxHTN Phase III trial,14
published in the New
England Journal of Medicine,1 Baxfendy
demonstrated statistically significant
and clinically meaningful efficacy for the treatment of patients
with hypertension on top of standard of care. At week 12, the
absolute reduction from baseline in mean seated SBP was 15.7 mmHg
(95% confidence interval [CI], -17.6 to -13.7) and the
placebo-adjusted reduction was 9.8 mmHg (95% CI, -12.6 to -7.0;
p<0.001) for the 2mg dose.
In the Bax24 Phase III trial,15
published in The
Lancet,2 Baxfendy
demonstrated statistically
significant, clinically meaningful and consistent blood pressure
reductions in patients with resistant hypertension who received
baxdrostat 2mg or placebo on top of standard of care. At week 12,
the absolute reduction from baseline in ambulatory 24-hour average
SBP was 16.6 mmHg (95% CI, -18.8 to -14.3) and the placebo-adjusted
reduction was 14.0 mmHg (95% CI, -17.2, -10.8; p<0.0001).
Efficacy was observed throughout the 24-hour period, including
early morning, when patients with hypertension are at a higher risk
of cardiovascular events.16,17
Baxfendy was generally
well-tolerated in the trials, with no unanticipated safety
findings.
Baxfendy is approved in the US
and other countries as a first-in-class ASI for adults with
hypertension not adequately controlled on other therapies, with
regulatory filings currently under review in other major regions,
including Japan and China.
Baxfendy is a first-in-class,
highly selective and potent ASI designed to lower blood pressure in
a new way by specifically inhibiting the production of
aldosterone,18
a hormone that raises blood pressure
to unhealthy levels and increases the risk of heart and kidney
problems.11-13
Notes
Persistently uncontrolled hypertension
Hypertension is a medical condition characterised by consistently
high blood pressure levels, affecting an estimated 1.4 billion
people worldwide.3,19,20
Over time, this can damage blood
vessels and vital organs, increasing the risk of serious health
problems such as heart attack, stroke, heart failure and kidney
disease. 19,20
Treated but uncontrolled patients with hypertension are at a
significantly greater risk of all-cause mortality, heart-disease
specific mortality, stroke-related mortality, CVD-specific
mortality and dementia than patients whose hypertension is
controlled. A large meta-analysis found that lowering systolic
blood pressure by 10 mmHg can reduce the risk of major adverse
cardiovascular events by around 20%,21
underscoring the urgent need for new
treatments that target a key hypertension pathway at its
source.
An observational study of nearly 60,000 patients studied over a
median of 9.7 years showed that a 9.5 mmHg increase in SBP was
associated with a 30% increase in risk of all-cause mortality and
41% increase in risk of cardiovascular death.22
Studies have shown that increased
night-time blood pressure is associated with higher cardiovascular
risk,23,24
and patients with hypertension have a
higher risk of cardiovascular events like heart attack, stroke and
death around the time of their morning blood pressure
surge.16,17
Epidemiological data indicate that a
10 mmHg decrease in SBP is associated with a roughly 20% lower risk
of serious cardiovascular events.21
Uncontrolled hypertension refers to persistently elevated blood
pressure despite the use of two or more medications, while
resistant hypertension, a more severe form, remains elevated
despite treatment with three or more medications. Guidelines
currently recommend that in patients with hypertension, treated BP
values should be targeted to 130/80 mmHg or lower in most
patients.19,25
Aldosterone, a hormone that can raise blood pressure to unhealthy
levels by promoting sodium and water retention,11,12
is a key contributor to persistently
uncontrolled hypertension. Elevated aldosterone levels, along with
factors such as obesity, high salt intake and various genetic or
secondary conditions,26
are strongly associated with poor
blood pressure control and the progression of heart failure and
kidney disease. When left untreated, hypertension significantly
increases the risk of cardiovascular and kidney-related
complications.8,19,25
BaxHTN trial
The BaxHTN Phase III trial14
had three different evaluation periods
that supported the following endpoints: The primary endpoint was
assessed during a 12-week double-blind, placebo-controlled period.
A total of 796 patients were randomised in a 1:1:1 ratio to
receive Baxfendy 2mg, 1mg or placebo once daily on top of standard
of care [two antihypertensive agents at baseline, one of which is a
diuretic for uncontrolled hypertension and ≥ 3
antihypertensive agents at baseline, one of which is a diuretic for
resistant hypertension]. The primary efficacy endpoint was the
difference in mean change from baseline in seated SBP at week 12
between participants treated with Baxfendy (2mg or 1mg separately) and participants treated
with placebo.
Persistence of efficacy was assessed during a randomised withdrawal
period from week 24 to week 32. Approximately 300 patients treated
with Baxfendy 2mg were re-randomised in a 2:1 ratio to either
continue receiving baxdrostat 2mg or placebo for the 8 weeks. SBP
at the end of the 8 weeks was compared between placebo and
the Baxfendy 2mg dose. Long-term safety was assessed at the end
of the study (Week 52 followed by a 2-week safety follow-up visit)
compared to a standard-of-care arm and was consistent with that
observed during the 12-week double-blind treatment period. In a
post-hoc efficacy analysis on the clinically meaningful reductions
in seated SBP with Baxfendy were sustained over 52 weeks with a
placebo-adjusted reduction of 12.6 mmHg (95% CI, -16.7 to -8.5;
p<0.001) for the 2 mg dose.1
Additional confirmatory secondary endpoints include the effect
of Baxfendy versus placebo on seated SBP at week 12 in the
resistant hypertension subpopulation, the effect of
Baxfendy
versus placebo on seated diastolic
blood pressure at week 12, and proportion of participants achieving
seated SBP less than 130 mmHg at week 12.
Bax24 trial
The Bax24 Phase III trial15
was a randomised, double-blind,
placebo-controlled, parallel group study to evaluate the effects of
2mg Baxfendy versus placebo, administered once a day (QD)
orally, on the reduction of ambulatory SBP, as well as safety and
tolerability in participants with resistant hypertension. A total
of 218 patients were randomised in a 1:1 ratio to receive
Baxfendy
2mg or placebo once daily during a
12-week double-blind period. The primary efficacy endpoint was the
change from baseline in ambulatory 24-hour average SBP at Week
12.
Consistent 24-hour blood pressure control is an important clinical
outcome in patients with persistently uncontrolled hypertension.
Multiple studies have demonstrated that 24-hour blood pressure is a
more powerful predictor of cardiovascular events than a
clinic-based measurement.22
When 24-hour average systolic blood
pressure rises by 9.5 mmHg, the associated risk of all-cause
mortality increases by 30%.22
Additional secondary endpoints include the effect of baxdrostat
versus placebo on change from baseline in ambulatory night-time
average SBP, change from baseline in ambulatory daytime average
SBP, change from baseline in seated SBP, the number of participants
achieving ambulatory 24-hour average SBP of less than 130 mmHg,
change from baseline in ambulatory 24-hour average diastolic blood
pressure (DBP), change from baseline in ambulatory night-time
average DBP, change from baseline in the average ambulatory daytime
average DBP, change from baseline on seated DBP and the number of
participants achieving a nocturnal SBP dipping of greater than or
equal to 10%, all measured at Week 12. Occurrence of adverse events
was evaluated during the 12-week treatment period as well as during
a 2-week safety follow-up period.
In a key secondary endpoint, 70.6 percent of patients treated
with Baxfendy achieved ambulatory 24-hour average SBP of less
than 130 mmHg compared to 16.7 percent of patients receiving
placebo (Odds ratio 15.2 [95% CI 6.6, 35.2;
p<0.0001]),2
in line with the 2024 ESH guidelines
for the management of arterial hypertension.25
This corresponds to two patients
needing treatment (NNT) with Baxfendy rather than placebo for one additional patient to
achieve this blood pressure threshold at week
12.27
Baxfendy
and the clinical development
programme
Baxfendy is a first-in-class,
highly selective and potent, oral, small molecule that inhibits
aldosterone synthase,18
an enzyme encoded by the CYP11B2 gene,
which is responsible for the synthesis of aldosterone in the
adrenal gland.12
In clinical trials,
Baxfendy
was observed to significantly lower
aldosterone levels without affecting cortisol levels across a wide
range of doses.28,29
As part of a broad development programme, Baxfendy is currently being investigated in clinical trials
in other conditions where high aldosterone plays a role in
elevating cardiorenal risk, including as a monotherapy for primary
aldosteronism,30
and in combination with dapagliflozin
for chronic kidney disease and hypertension,31,32
and the prevention of heart failure in
patients with hypertension.33
AstraZeneca acquired Baxfendy through its purchase of CinCor Pharma, Inc. in
February 2023.34
AstraZeneca in CVRM
Cardiovascular, Renal and Metabolism (CVRM), part of
BioPharmaceuticals, forms one of AstraZeneca's main disease areas
and is a key growth driver for the Company. By following the
science to understand more clearly the underlying links between the
heart, kidneys, liver and pancreas, AstraZeneca is investing in a
portfolio of medicines for organ protection by slowing or stopping
disease progression, and ultimately paving the way towards
regenerative therapies. The Company's ambition is to improve and
save the lives of millions of people, by better understanding the
interconnections between CVRM diseases and targeting the mechanisms
that drive them, so we can detect, diagnose and treat people
earlier and more effectively.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Disease, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and follow the
Company on Social Media @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1.
Flack
JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and
Resistant Hypertension. N Engl J Med. 2025. Aug
30:10.1056/NEJMoa2507109. doi: 10.1056/NEJMoa2507109.
2.
Azizi
M, Bax24 investigators, et al. Effect of baxdrostat on ambulatory
blood pressure in patients with resistant hypertension (Bax24): a
phase 3, randomised, double-blind, placebo-controlled trial.
Lancet. 2026 Mar 7;407(10532):988-999.
3.
World Health Organization. Global report on
hypertension 2025: high stakes: turning evidence into action.
2025. https://iris.who.int/handle/10665/382841.
Accessed September 2025
4.
Carey
RM, et al. Prevalence of Apparent Treatment-Resistant Hypertension
in the United States. Hypertension.
2019;73(2):424-431.
5.
NCD
Risk Factor Collaboration (NCD-RisC). Worldwide trends in
hypertension prevalence and progress in treatment and control from
1990 to 2019: a pooled analysis of 1201 population-representative
studies with 104 million participants. Lancet. 2021 Sep
11;398(10304):957-980.
6.
Rapsomaniki
E, et al. Blood pressure and incidence of twelve cardiovascular
diseases: lifetime risks, healthy life-years lost, and age-specific
associations in 1·25 million people. Lancet. 2014 May
31;383(9932):1899-911.
7.
GBD
2019 Risk Factors Collaborators. Lancet.
2020;396:1223-1249.
8.
Zhou
D, et al. Uncontrolled hypertension increases risk of all-cause and
cardiovascular disease mortality in US adults: the NHANES III
Linked Mortality Study. Sci Rep. 2018: 20;8(1):9418.
9.
Hall
ME et al. Weight-loss strategies for prevention and treatment of
hypertension: a scientific statement from the American Heart
Association. Hypertension. 2021;78:e38-e50.
10.
GBD
2023 Disease and Injury and Risk Factor Collaborators. Burden of
375 diseases and injuries, risk-attributable burden of 88 risk
factors, and healthy life expectancy in 204 countries and
territories, including 660 subnational locations, 1990-2023: a
systematic analysis for the Global Burden of Disease Study 2023.
Lancet. 2025;406:1873-1922.
11.
Inoue
K, et al. Serum aldosterone concentration, blood pressure, and
coronary artery calcium: the Multi-Ethnic Study of Atherosclerosis
[including online supplement]. Hypertension.
2020;76(1):113-120.
12.
Cannavo
A, et al. Aldosterone and mineralocorticoid receptor system in
cardiovascular physiology and pathophysiology. Oxid Med Cell
Longev. 2018;2018:1204598.
13.
Xanthakis
V, Vasan RS. Aldosterone and the risk of hypertension. Curr
Hypertens Rep. 2013;15(2):102-107.
14.
ClinicalTrials.gov. A Study to Investigate the
Efficacy and Safety of Baxdrostat in Participants With Uncontrolled
Hypertension on Two or More Medications Including Participants With
Resistant Hypertension (BaxHTN). Available at: https://clinicaltrials.gov/study/NCT06034743.
Accessed April 2026.
15.
ClinicalTrials.gov. A Study to Investigate the
Effect of Baxdrostat on Ambulatory Blood Pressure in Participants
With Resistant Hypertension (Bax24). Available at:
https://clinicaltrials.gov/study/NCT06168409.
Accessed April 2026.
16.
Renna
NF, et al. Morning blood pressure surge as a predictor of
cardiovascular events in patients with hypertension. Blood Press
Monit. 2023;28(3):149-157.
17.
Kario
K et al. Morning hypertension: the strongest independent risk
factor for stroke in elderly hypertensive patients. Hypertens Res.
2006;29(8):581-7.
18.
Bogman
K, et al. Preclinical and early clinical profile of a highly
selective and potent oral inhibitor of aldosterone synthase
(CYP11B2). Hypertension. 2017;69:189-96.
19.
McEvoy JW, et al. 2024 ESC Guidelines for the
management of elevated blood pressure and
hypertension. Eur Heart
J.2024;45(38):3912-4018.
20.
Whelton
PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA
Guideline for the Prevention, Detection, Evaluation, and Management
of High Blood Pressure in Adults: Executive Summary. Hypertension.
2018;71(6):1269-1324.
21.
Ettehad
D, et al. Blood pressure lowering for prevention of cardiovascular
disease and death: a systematic review and meta-analysis. Lancet.
2016;387:957-67.
22.
Staplin
N, et al. Relationship between clinic and ambulatory blood pressure
and mortality: an observational cohort study in 59 124 patients.
Lancet. 2023;401(10393):2041-2050.
23.
Narita
K, et al. Nighttime Home Blood Pressure Is Associated With the
Cardiovascular Disease Events Risk in Treatment-Resistant
Hypertension. Hypertension. 2022;79(2):e18-e20.
24.
Niiranen
TJ, Mäki J, Puukka P, Karanko H, Jula AM. Office, home, and
ambulatory blood pressures as predictors of cardiovascular risk.
Hypertension. 2014 Aug;64(2):281-6.
25.
Kreutz R, et al. 2024 European Society of
Hypertension clinical practice guidelines for the management of
arterial hypertension. Eur J Intern
Med. 2024
Aug;126:1-15.
26.
van
Oort S, et al. Association of cardiovascular risk factors and
lifestyle behaviors with hypertension: a mendelian randomization
study. Hypertension. 2020;76(6):1971-1979.
27.
Williams
B, et al. Effect of baxdrostat on 24-hour ambulatory blood pressure
in patients with resistant hypertension: the Bax24 trial. Presented
at: American Heart Association Scientific Sessions 2025; November
7–10, 2025; New Orleans, LA.
28.
Freeman
MW, et al. Results from a phase 1, randomized, double-blind,
multiple ascending dose study characterizing the pharmacokinetics
and demonstrating the safety and selectivity of the aldosterone
synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res.
2023;46(1):108-118.
29.
Freeman
MW, et al. Phase 2 trial of baxdrostat for treatment-resistant
hypertension. N Engl J Med. 2023;388(5):395-405.
30.
ClinicalTrials.gov. A Study to Assess Efficacy and
Safety of Baxdrostat in Participants With Primary Aldosteronism
(BaxPA). Available at: https://clinicaltrials.gov/study/NCT07007793.
Accessed April 2026.
31.
ClinicalTrials.gov. A Phase III Study to
Investigate the Efficacy and Safety of Baxdrostat in Combination
With Dapagliflozin on CKD Progression in Participants With CKD and
High Blood Pressure. Available at: https://clinicaltrials.gov/study/NCT06268873.
Accessed April 2026.
32.
ClinicalTrials.gov. A Phase III Renal Outcomes and
Cardiovascular Mortality Study to Investigate the Efficacy and
Safety of Baxdrostat in Combination With Dapagliflozin in
Participants With Chronic Kidney Disease and High Blood Pressure
(BaxDuo-Pacific). Available at: https://clinicaltrials.gov/study/NCT06742723.
Accessed April 2026.
33.
ClinicalTrials.gov. Phase III Study Investigating
Heart Failure and Cardiovascular Death With Baxdrostat in
Combination With Dapagliflozin (Prevent-HF). Available at:
https://clinicaltrials.gov/study/NCT06677060.
Accessed April 2026.
34.
AstraZeneca 2023. Acquisition of CinCor Pharma
complete. Available at: https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-acquires-cincor-for-cardiorenal-asset.html.
Accessed April 2026.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date: 16 November 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|